The GLP-1 receptor agonists have been associated with a significant reduction in pancreatic and other obesity-related cancers, likely due to their combined effects on weight loss, improved metabolic and inflammatory profiles, and direct anti-proliferative actions [92]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.